BioSpace News Archive

After a slight delay, things remain on schedule for Alnylam’s new $200 million manufacturing facility. The company expects the site to open in late 2019, which could follow regulatory approval of patisiran, its RNAi treatment for Hereditary ATTR Amyloidosis.

As its core semiconductor and smartphone businesses slow down, South Korea’s Samsung Group has announced a broad investment into new areas. Those areas include artificial intelligence (AI), 5G mobile technology, electronic components for the automotive industry, and biopharmaceuticals.

Watertown, Massachusetts-based SQZ Biotechnologies completed an oversubscribed Series C financing worth $72 million. New investors included Everblue, Illumina Ventures, Invus, Orient Life, and Viva Ventures Biotech Group.

Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.

Ambys Medicines, based in Redwood City, California, has launched in an unusual deal with Osaka, Japan’s Takeda Pharmaceutical Company.

Shares of Novo Nordisk are down about five percent this morning after the company reported an overall decline in sales during the second quarter of this year. Sales were particularly disappointing in North America.

Two days after Boston Scientific laid off 85 employees at a Burlington, Mass. manufacturing site, the company forked over up to $160 million to acquire California stent maker Veniti, Inc. The deal marks the third acquisition for Boston Scientific in two months.

A New York Republican Congressman and his son have been charged with insider trading. U.S. Rep. Chris Collins was a board member for Australia-based Innate Immunotherapeutics. The government charged he used that information to help his son make timely trades.

The pharma industry has developed ad campaigns to tout the efficacy of its branded products to consumers, often using celebrities to add his or her personal stamp onto a pharmaceutical product.

Atlantic Healthcare plc (Atlantic Healthcare), a specialist gastrointestinal (GI) pharmaceutical company, developing treatments for inflammatory bowel disease and other GI diseases, has appointed John Temperato as U.S. President and Chief Operating Officer, to lead the commercialisation programme of alicaforsen in the U.S.